Home › Triple-Negative Breast Cancer
Triple-Negative Breast Cancer clinical trials recruiting in the U.S.
143 studies for Triple-Negative Breast Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX42 studies
- New York City, NY33 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA24 studies
- San Antonio, TX24 studies
- Arlington, VA21 studies
- St. Louis, MO21 studies
- Atlanta, GA19 studies
- Dallas, TX18 studies
- New Haven, CT16 studies
- Grand Rapids, MI16 studies
- Chicago, IL16 studies
- Columbus, OH15 studies
- Tampa, FL14 studies
- Queens, NY14 studies
- Durham, NC14 studies
- Philadelphia, PA13 studies
- Seattle, WA13 studies
- San Francisco, CA13 studies
- Denver, CO12 studies
- Austin, TX12 studies
- Orlando, FL12 studies
- Washington, DC12 studies
- Baldwin Park, CA12 studies
- West Valley City, UT12 studies
- Baltimore, MD11 studies
- Pittsburgh, PA11 studies
- San Diego, CA11 studies
- Cleveland, OH11 studies
- Rochester, MN11 studies
- Edison, NJ11 studies
- Miami, FL10 studies
- Birmingham, AL10 studies
- Salt Lake City, UT9 studies
- Aurora, CO9 studies
- Oklahoma City, OK9 studies
- Jacksonville, FL9 studies
- Portland, OR9 studies
- Sarasota, FL8 studies
By state
- Alabama13 studies
- Arizona16 studies
- Arkansas3 studies
- California53 studies
- Colorado21 studies
- Connecticut20 studies
- Delaware3 studies
- District of Columbia8 studies
- Florida45 studies
- Georgia25 studies
- Illinois21 studies
- Indiana10 studies
- Iowa8 studies
- Kansas5 studies
- Kentucky6 studies
- Louisiana6 studies
- Maine3 studies
- Maryland17 studies
- Massachusetts24 studies
- Michigan28 studies
- Minnesota16 studies
- Missouri24 studies
- Nebraska6 studies
- Nevada6 studies
- New Jersey20 studies
- New Mexico3 studies
- New York47 studies
- North Carolina22 studies
- Ohio29 studies
- Oklahoma10 studies
- Oregon12 studies
- Pennsylvania23 studies
- Rhode Island5 studies
- South Carolina10 studies
- South Dakota7 studies
- Tennessee31 studies
- Texas59 studies
- Utah22 studies
- Virginia29 studies
- Washington21 studies
- Wisconsin7 studies
Recently updated studies
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Nov 13, 2026 · NCT07619534PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07069595Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05422794Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03606967Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05111561A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 9, 2026 · NCT07652242A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07029399A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07318805Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06393374A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150664Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07341867Study of XB010 in Subjects With Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT06545331Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT05318469A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06908928Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04981119A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07705334From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.